Dementia and Alzheimer Disease

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD. [LISTEN TIME: 32 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 8, 2022.

The assistant professor of neurology at the University of Pennsylvania discussed the similarities observed between the results of neurological exams in patients with COVID-19 vs other respiratory infections. [WATCH TIME: 3 minutes]

Seth M. Keller, MD, chair of the Section for Adults With IDDs at AAN, shared his perspective on the state of care for these individuals and the need to improve the difficulties they face when transitioning out of pediatric care.

In an AAN 2022 Hot Topics plenary session, Miranda E. Orr, PhD, highlighted the potential of targeting senescent cells with senolytics as a therapeutic approach to age-related diseases such as Alzheimer disease, and detailed the ongoing phase 2 SToMP-AD clinical trial (NCT04685590).

The professor of neurology at NYU Langone Grossman School of Medicine discussed her talk at AAN 2022 on neurological sequelae and follow-up in hospitalized and nonhospitalized patients with COVID-19. [WATCH TIME: 8 minutes]

Here's what is coming soon to NeurologyLive®.

On fluorodeoxyglucose PET, pepinemab slowed or reversed decline in metabolic activity in all 26 brain regions observed, with significant benefit found in 15 regions.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Sage Therapeutics’ investigational NMDA receptor positive allosteric modulator was well-tolerated, with signs of cognitive and functional improvements reported for patients with AD in the phase 2 LUMINARY study.

Neurology News Network for the week ending April 2, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 1, 2022.

Annual progression rates to dementia were 14.7% for those with mild behavior impairment and 8.3% for the those without neuropsychiatric symptoms, with reversion rates of 2.5% and 5.3%, respectively, for each group.

The company anticipates the first patient to be screened in May 2022, with a primary end point of cognitive decline at 18 months, measured by the Clinical Dementia Rating-Sum of Boxes.

In preclinical studies, the investigational agent has demonstrated a clearance of both pyroglutamate modified and unmodified Aß plaque in brain tissue concentrations.

The neurologist and assistant professor at the University of Toronto addressed the issues within Alzheimer drug development, the boom of biomarkers, and how retinal imaging can have a multilevel positive impact.

Abnormal scores on cognitive testing persisted in 50% of patients without a pre-COVID history of cognitive abnormalities, irrespective of the presence or absence of a neurological complication during hospitalization.

Here's what is coming soon to NeurologyLive®.

Jefferson Kinney, PhD, founding chair of the department of brain health at UNLV, discussed the ways a new NIH grant will assist in building a robust neuroscience research infrastructure at the Center for Neurodegeneration and Translational Neuroscience.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 25, 2022.

The neurologist and assistant professor at the University of Toronto discussed the different valued biomarkers to assess Alzheimer disease and whether the introduction of retinal imaging changes clinician perception of the most valuable biomarkers. [WATCH TIME: 3 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.